<DOC>
	<DOC>NCT02143388</DOC>
	<brief_summary>This is an randomized, controlled, multicenter phase II clinical trial. The purpose of this study is to evaluate acute toxicity and efficacy of concurrent cisplatin chemoradiation with or without capecitabine as adjuvant chemotherapy in local advanced high risk nasopharyngeal carcinoma.</brief_summary>
	<brief_title>Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Phase II Randomized Control Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Newly histologic diagnosis of nasopharyngeal carcinoma(WHO II/III) Clinical stage III~IVb(UICC 7th) Meet at least one factor below :1 primary tumor SUVmax&gt;10 in 18FFDG PET/CT;2 primary tumor volume＞30cm3;3 mutiple metastatic cervical lymph node with at least one's short diameter＞4cm; 4 T4N2M0; 5 T14N3M0;6 EBVDNA＞2×10E4 copy/l Range from 18～70 years old WBC count ≥ 4×109/L，Hemoglobin ≥ 100g/L， platelet count ≥ 100×109/L ALT or AST ＜ 2.5×ULN、bilirubin ＜ 1.5×ULN OSerum creatinine ＜ 1.5×ULN Central nervous system metastases Suitable for local treatment Uncontrolled seizure disorder or other serious neurologic disease Clinically significant cardiac or respiratory disease Drug or alcohol addition Do not have full capacity for civil acts Severe complication, active infection Concurrent immunotherapy or hormone therapy for other diseases Pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Local advanced</keyword>
	<keyword>high risk</keyword>
	<keyword>nasopharyngeal carcinoma</keyword>
</DOC>